S
Saluda Medical
Dedicated to improving the lives of people by providing personalized, responsive, and efficient neuromodulation therapy (spinal cord stimulation )
About Saluda Medical
Saluda Medical is a pioneering healthcare startup that operates in the field of neuromodulation, specifically spinal cord stimulation (SCS). The company has developed a unique technology that measures the spinal cord's physiological response to stimulation, using Evoked Compound Action Potentials (ECAPs). ECAPs are electrical signals generated by the nervous system, and Saluda's technology allows for the first time, an objective measurement of these signals in the spinal cord.
The company's primary product is the Evoke® System, which uses ECAPs to provide smart neuromodulation therapy. This system listens and responds to each patient's unique neural signature, providing a more personalized and effective treatment. The Evoke® System has shown clinical superiority in a double-blinded, randomized clinical trial, demonstrating enduring patient outcomes.
Saluda Medical's business model revolves around providing this innovative technology to clinicians and healthcare providers. By offering a more objective and accurate measure of neural activation, the company empowers clinicians to provide more consistent pain relief to their patients. This is particularly important as neural activation is the mechanism that drives pain inhibition.
In terms of future potential, Saluda's proprietary SmartLoop™ technology could have broad applications in the field of neuromodulation, including therapies such as vagal nerve, sacral nerve, and deep brain stimulation. This suggests that the company has a significant growth potential in the expanding market of neuromodulation therapies.
Source: Dealroom company dataAt a glance
- Status
- Listed
- Founded
- 2013
- Headquarters
- Sydney, Australia
- Listing
- IPO 2025
- Employees
- 482
- Open positions
- 15
- Dealroom signal
- 72.1/100
- Industry
- Health
- Sub-industry
- Medical Devices
- Sector
- Health Tech & Medtech, Neurology, Neuromodulation and Neurostimulation, Chronic Disease, Spinout, Tech for Patients, Hard Tech, pain care, DT and LS, science-based
- Technology
- Deep Tech
- Business model
- Manufacturing
- Client focus
- b2b
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| POST IPO DEBTDebt | Jun 2026 | $25M | — | Perceptive Advisors | ↗ |
| IPOOther financing | Dec 2025 | $65M | $501M | Undisclosed | ↗ |
Growth signals
Latest recorded traffic for Saluda Medical is 7.1K monthly website visits, down 12.3% over the last three months. Saluda Medical's team declined 1% over the past year.
Open positions
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A1 investor entered at this stage
BioScience Managers Limited
Series B and later11 investors entered at this stage
Action Potential Venture Capital
Redmile Group- PNPneumRx
Boston Scientific
Fidelity Investments
Wellington Management
T. Rowe Price
TPG
The Rise Fund (TPG)- PCPiper Heartland Healthcare Capital
Perceptive Advisors
Other known investors1 additional known investor
CSIRO
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Saluda Medical on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Saluda Medical’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.







